Agios Pharmaceuticals was upgraded to buy from hold at Canaccord Genuity. $90 price target. PKD treatment is showing meaningful clinical progress, Canaccord said.
Axiall (AXLL) was downgraded to neutral from overweight at JPMorgan. The valuation is less attractive, based on a $33 price target, JPMorgan said.
Concho Resources (CXO - Get Report) was upgraded to overweight at Morgan Stanley. $173 price target. The company has long-term oil exposure with significant upside growth potential, Morgan Stanley said.
ON Semiconductor (ON - Get Report) was upgraded to overweight at Pacific Crest. $13 price target. The company should see higher incremental ADAS content and synergies from the Fairchild purchase, Pac Crest said.